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Schizophrenia is a chronic clinical syndrome with a lifetime prevalence of 0.3-.0.66%.1 
Schizophrenia is characterized by several psychopathologic domains, including positive 
symptoms, negative symptoms, affective and cognitive symptoms. The positive symptoms 
include psychotic symptoms such as hallucinations, delusions and disorganization of thought 
and behavior. Positive symptoms can often be diminished with antipsychotics and usually 
only occur periodically. Negative symptoms of schizophrenia include the flattening of affect, 
alogia, avolition, apathy and asociality. In contrary to positive symptoms of schizophrenia, 
negative symptoms often persist and about 25% of all patient with schizophrenia suffer 
from severe and persistent negative symptoms.2 Treatment options for negative symptoms 
of schizophrenia are limited and often yield disappointing results.3-5 The cognitive symptoms 
include deficits in working memory, executive functioning, processing speed and difficulty in 
paying attention. Cognitive symptoms are also enduring features of schizophrenia and may 
co-occur with negative symptoms. Positive symptoms, negative symptoms and cognitive 
symptoms are usually invalidating and interfere with every-day functioning of patients. 
Patients with schizophrenia have a decreased life expectancy of 12-15 years, mainly due to 
its association with smoking, the metabolic syndrome, obesity, little exercise and to a lesser 
extend an increased rate of suicide.1
 Schizophrenia is a heterogeneous syndrome, and the prognosis of schizophrenia varies. 
About one third of the patients have a good prognosis, one third an intermediate prognosis 
and one third a poor prognosis as expressed in symptomatology and social outcome.6 
Negative and cognitive symptoms of schizophrenia are associated with a poorer prognosis 
and may be a major cause of the functional impairment associated with schizophrenia.7 
Indeed, negative symptoms of schizophrenia have been associated with impaired work/
school functioning,8,9 poor social functioning8,10 and higher family burdens.11 Earlier research 
on schizophrenia focused on the positive symptoms of schizophrenia. However, the 
relationship of positive symptoms and functioning appears to be weak.9 It seems that positive 
symptoms do not constantly hamper a patients ability to work, study or engage in social 
activities. On the one hand this may be due to the available antipsychotics to treat positive 
symptoms, on the other hand patients may learn to cope with or adequately compensate for 
these symptoms. Whereas positive symptoms do not constantly hamper daily functioning, 
negative symptoms are associated with impairments in daily performance. Patients with 
predominant negative symptoms are often unemployed, the majority do not have long-
term intimate relationships or children, and they often experience problems in living 
independently and keeping their lives organized. Therefore it is important to investigate 
the cause and possible therapeutic interventions to diminish negative symptoms in order 
to improve social outcomes for people suffering from schizophrenia and related disorders. 
This thesis will focus on the negative symptoms of schizophrenia. It will discuss possible 
treatment options for negative symptoms and the underlying possible neural substrates of 




Multidimensionality of negative symptoms
A distinction can be made between primary and secondary negative symptoms.12 Primary 
negative symptoms may compromise a core feature thought to be intrinsic to schizophrenia 
and often occur earlier in life than positive symptoms. Secondary negative symptoms refer 
to negative symptoms seemingly caused by other factors such as positive symptoms, side 
effects of medication or social isolation. For example, social withdrawal may be secondary 
to paranoid delusions, stigmatization may contribute to social isolation and a side effect 
of antipsychotic medication can be blunted affect or reduction of initiative.13 In clinical 
practice, it is difficult to make a clear distinction between primary and secondary negative 
symptoms. In addition, primary and secondary negative symptoms may co-exist. 
 Recently there has been a shift to an approach of negative symptoms based on 
symptom dimensions. Originally negative symptoms were considered to constitute 
one dimension, but several studies have found two, three and even five dimensions of 
negative symptoms.7,14,15 Most studies have found two factors in negative symptoms.7,15,16 
The first factor seems related to social-emotional withdrawal/avolition and the second 
factor to expressive deficits such as diminished verbal and non-verbal expression.7,15-17 
Interestingly, there is evidence that the social-emotional withdrawal/avolition factor, 
but not the expressive deficits factor, is related to deficits in anticipatory pleasure.18-20 
Acknowledging the multidimensionality of negative symptoms, and focusing on expressive 
deficits and social-emotional withdrawal/avolition as two separate domains can help to 
further improve diagnosis and treatment options and to better understand their underlying 
pathophysiology.16,17
Neural correlates of negative symptoms
For a better understanding of negative symptoms, the investigation of the underlying 
neurobiology is important. Several neuroimaging studies have found reduced activation 
of the prefrontal cortex (PFC), and more specifically in the dorsolateral prefrontal cortex 
(DLPFC), in patients with negative symptoms of schizophrenia.21-26 Also, decreased levels of 
perfusion of the thalamus and abnormalities in the anterior cingulate cortex (ACC) and the 
striatum have been found.27-30 Additionally, fMRI studies have shown a negative correlation 
between ventral-striatal activation during reward anticipation and apathy,31 and evidence 
for a relationship between dysfunctional striato-cortical connectivity and negative 
symptom severity.32 The PFC, ACC, the striatum and thalamus are brain regions involved in 
reward and motivation and abnormalities in information processing on the fronto-striatal 
networks may play a part in negative symptoms of schizophrenia. Also, decreased blood 
flow in the fronto-parietal network in patients with negative symptoms has been found.25,33 




 The abnormal brain activity found may be reflected by changes in several 
neurotransmitters and thus in the neuronal metabolism in these brain regions. In the 
prefrontal cortex, dopaminergic transmission is primarily mediated by D1 receptors, and 
there is evidence of D1 dysfunction in patients with negative symptoms.36,37 Furthermore, a 
relationship between reduced N-Acetyl Aspartate (NAA) concentration in the frontal cortex 
and severity of negative symptoms has been found.38-40 In addition, there is evidence for a 
correlation of severity of negative symptoms and glutamate levels in the ACC.41 
 Thus, changes in several transmitters may be implied in the pathophysiology of 
negative symptoms. Dysregulation of the prefrontal-striatal-thalamic and fronto-parietal 
neurocircuits may be involved in the pathogenesis and maintenance of negative symptoms, 
but the underlying mechanism is not fully understood and further research is needed to 
better understand the underlying neural substrates. 
rTMS treatment of negative symptoms
As mentioned earlier, treatment options for negative symptoms of schizophrenia are 
limited and often yield disappointing results.3-5 A recent large meta-analysis on treatments 
of negative symptoms of schizophrenia including 168 randomized-placebo controlled 
trials found a significant reduction of negative symptoms after treatment with second-
generation antipsychotics, antidepressants, the combination of these pharmacological 
agents, glutamatergic medications and psychological interventions.42 However, the effect 
of treatment was limited, as none of the treatments reached the threshold for clinically 
significant improvement.42 
 Repetitive Transcranial Magnetic Stimulation (rTMS) is an emerging treatment option 
in psychiatry which has been approved by the Food and Drugs Administration for the 
treatment of major depressive disorder. It a relatively safe and non-invasive method to 
change neuronal activity via electromagnetic induction.43 By using alternating magnetic 
fields at a certain frequency it can induce an electric current in the brain tissue underlying 
the stimulation site. High-frequency rTMS increases local cortical excitability and low-
frequency rTMS decreases excitability. Besides changing brain activity in the directly 
stimulated area, rTMS has also shown to change brain activity in connected brain areas.44 
Using rTMS treatment to increase brain activity in the prefrontal cortex in patients with 
negative symptoms may adjust abnormalities in the fronto-striatal or fronto-parietal 
networks, thereby diminishing negative symptoms of schizophrenia. Up to date five meta-
analysis on rTMS treatment of negative symptoms have been published.42,45-48 One meta-
analysis involving five studies48 did not find a significant improvement of negative symptoms 
after rTMS. A meta-analysis on brain stimulation (both rTMS and Transcranial Direct-
Current Stimulation) including eight studies42 also did not find a significant improvement 




included studies using rTMS. One, including seven studies, found a trend for improvement 
of negative symptoms,47 the other two containing a larger number of studies (nine and 
thirteen) found a positive treatment effect.45,46 In conclusion, there is a growing body of 
evidence for the efficacy of rTMS treatment for negative symptoms of schizophrenia, but 
little is known about the optimum rTMS treatment parameters and underlying neuronal 
working mechanisms. 
The aims of this thesis are:
1)  To investigate the efficacy of treatment with rTMS for negative symptoms of 
schizophrenia, including the effects on brain activation. 
2) To investigate the underlying neural substrates of negative symptoms of schizophrenia
Outline of the thesis
This thesis focuses on the treatment of negative symptoms of schizophrenia with repetitive 
transcranial magnetic stimulation (rTMS) and on the underlying neural substrates of 
negative symptoms. The first section of the thesis, chapter 2-6, focus on rTMS treatment of 
negative symptoms of schizophrenia, including effects on brain activation of the treatment. 
The second section of the thesis, chapter 6 and 7, examines the underlying neural substrates 
of negative symptoms. 
 In the second chapter, a review of the literature and the results of a meta-analysis 
on the treatment of negative symptoms of schizophrenia with rTMS is presented and 
discussed. The third chapter presents the results of a double blind randomized control trial 
of rTMS treatment for negative symptoms of schizophrenia. The forth chapter presents and 
discusses the results of a combined rTMS treatment and fMRI neuroimaging study. The fifth 
chapter presents the results of a combined rTMS treatment and H-Magnetic Resonance 
Spectroscopy (MRS) study. 
 The second section, chapter 6 and 7, discusses the possible underlying neural substrates 
of negative symptoms of schizophrenia based on the results of two fMRI neuroimaging 
studies conducted in patients with schizophrenia and healthy controls. These studies also 
analyze the neural substrates of the two domains of negative symptoms. The eight and final 
chapter of this thesis include the summary and discussion. 

